Nina S. Kjellson Sells 5,401 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) Director Nina S. Kjellson sold 5,401 shares of the company's stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $13.76, for a total transaction of $74,317.76. Following the completion of the transaction, the director now directly owns 443,885 shares of the company's stock, valued at approximately $6,107,857.60. The trade was a 1.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Tyra Biosciences Trading Down 2.1 %

NASDAQ TYRA traded down $0.26 during trading hours on Tuesday, reaching $12.13. The company's stock had a trading volume of 432,196 shares, compared to its average volume of 278,878. The business has a 50-day simple moving average of $14.92 and a 200 day simple moving average of $18.60. Tyra Biosciences, Inc. has a 52 week low of $11.91 and a 52 week high of $29.60. The stock has a market cap of $613.78 million, a PE ratio of -7.53 and a beta of 1.05.

Hedge Funds Weigh In On Tyra Biosciences

A number of large investors have recently bought and sold shares of the business. Alta Partners Management Company L.P. acquired a new stake in shares of Tyra Biosciences in the fourth quarter valued at approximately $56,716,000. FMR LLC increased its stake in shares of Tyra Biosciences by 0.8% in the third quarter. FMR LLC now owns 3,372,850 shares of the company's stock valued at $79,296,000 after purchasing an additional 26,187 shares during the period. Janus Henderson Group PLC acquired a new stake in shares of Tyra Biosciences in the third quarter valued at approximately $24,994,000. State Street Corp increased its stake in shares of Tyra Biosciences by 4.4% in the third quarter. State Street Corp now owns 384,732 shares of the company's stock valued at $9,045,000 after purchasing an additional 16,248 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in shares of Tyra Biosciences by 1.1% in the third quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company's stock valued at $8,667,000 after purchasing an additional 3,896 shares during the period. Institutional investors own 84.14% of the company's stock.

Wall Street Analysts Forecast Growth

TYRA has been the topic of several research analyst reports. Bank of America raised shares of Tyra Biosciences from a "neutral" rating to a "buy" rating and increased their price target for the stock from $22.00 to $31.00 in a research report on Friday, October 18th. UBS Group initiated coverage on shares of Tyra Biosciences in a research report on Tuesday, January 7th. They set a "buy" rating and a $28.00 price target on the stock. Wedbush reaffirmed an "outperform" rating and set a $28.00 price target on shares of Tyra Biosciences in a research report on Friday, October 25th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $30.00 price target on shares of Tyra Biosciences in a research report on Monday, January 13th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Tyra Biosciences has an average rating of "Buy" and an average target price of $30.50.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.